Home › Compare › TCON vs QYLD

TCON vs QYLD: Dividend Comparison 2026

TCON yields 6211.18% · QYLD yields 12.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCON wins by $514736922231177.94M in total portfolio value
10 years
TCON
TCON
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full TCON calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
12.24%
Share price
$16.70
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$6,038.84
Full QYLD calculator →

Portfolio growth — TCON vs QYLD

📍 TCON pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCONQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCON + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TCON pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCON
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,040.82/yr
After 10yr DRIP, annual income (after tax)
$5,133.01/yr
At 15% tax rate, TCON beats the other by $424,094,818,850,315,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCON + QYLD for your $10,000?

TCON: 50%QYLD: 50%
100% QYLD50/50100% TCON
Portfolio after 10yr
$257368461115588.97M
Annual income
$249,467,540,500,185,400,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TCON right now

TCON
Analyst Ratings
14
Buy
2
Hold
Consensus: Buy
Altman Z
-44.2
Piotroski
6/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCON buys
0
QYLD buys
0
No recent congressional trades found for TCON or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCONQYLD
Forward yield6211.18% ✓12.24%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$514736922231177.94M ✓$26.5K
Annual income after 10y$498,935,081,000,370,800,000.00 ✓$6,038.84
Total dividends collected$513674666624982.00M ✓$28.5K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TCON vs QYLD ($10,000, DRIP)

YearTCON PortfolioTCON Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$631,818$621,118.01$10,384$1,224.49+$621.4K → TCON
2$37,352,078$36,676,032.53$10,900$1,388.18+$37.34M → TCON
3$2,066,348,794$2,026,382,070.58$11,576$1,590.76+$2066.34M → TCON
4$106,978,454,906$104,767,461,696.78$12,447$1,844.20+$106978.44M → TCON
5$5,183,619,185,269$5,069,152,238,519.27$13,567$2,164.97+$5183619.17M → TCON
6$235,102,301,025,325$229,555,828,497,087.03$15,003$2,576.05+$235102301.01M → TCON
7$9,981,906,672,630,884$9,730,347,210,533,788.00$16,853$3,110.04+$9981906672.61M → TCON
8$396,781,870,195,426,800$386,101,230,055,711,700.00$19,251$3,813.85+$396781870195.41M → TCON
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$22,390$4,756.08+$14768075916642.10M → TCON
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$26,548$6,038.84+$514736922231177.94M → TCON

TCON vs QYLD: Complete Analysis 2026

TCON — Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Full TCON Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TCON vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCON vs SCHDTCON vs JEPITCON vs OTCON vs KOTCON vs MAINTCON vs XYLDTCON vs JEPQTCON vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.